DVA: DaVita HealthCare Partners Inc. Stock

by  •  • Comments Off on DVA: DaVita HealthCare Partners Inc. Stock

SIC 809 – Miscellaneous Health And Allied Services, Not

Valuation
Market Cap ($M) 7,335.95
Enterprise Value ($M) 17,528.36
Book Value ($M) 2,224.80
Book Value / Share 24.61
Price / Book 3.30
NCAV ($M) -11,548.16
NCAV / Share -127.73
Price / NCAV -0.64

Profitability (mra)
Return on Invested Capital (ROIC) 0.04
Return on Assets (ROA) 0.03
Return on Equity (ROE) 0.23

Liquidity (mrq)
Quick Ratio 1.16
Current Ratio 1.20

Balance Sheet (mrq) ($M)
Current Assets 3,155.29
Assets 16,928.25
Liabilities 14,703.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 11,609.89
Operating Income 1,312.54
Net Income 560.40
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 1,564.57
Cash from Investing -630.35
Cash from Financing -1,121.13

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-09 13G/A Vanguard Group Inc 6.84 -17.58
02-01 13G/A BlackRock Inc. 5.40 -14.73
08-03 13D/A Berkshire Hathaway Inc 39.50 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-02-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI
2022-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT
2022-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S
2022-05-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2023-03-31 81,473 458,886 17.75
2023-03-30 64,493 430,699 14.97
2023-03-29 64,730 432,336 14.97
2023-03-28 50,092 312,730 16.02
2023-03-27 51,071 332,674 15.35

(click for more detail)

Similar Companies
AGL – agilon health, inc. CNVY – Convey Holding Parent, Inc.
CO – China Cord Blood Corp. FMS – Fresenius Medical Care AG & Co KGaA


Financial data and stock pages provided by
Fintel.io